How To Know If Pasithea Therapeutics Corp. (NASDAQ:KTTA) Is Expensive At $1.39. – Marketing Sentinel
Home  »  Business   »  How To Know If Pasithea Therapeutics Corp. (NASDAQ...

How To Know If Pasithea Therapeutics Corp. (NASDAQ:KTTA) Is Expensive At $1.39.

In last trading session, Pasithea Therapeutics Corp. (NASDAQ:KTTA) saw 1.07 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $1.39 trading at -$0.11 or -7.33% at ring of the bell on the day assigns it a market valuation of $31.82M. That closing price of KTTA’s stock is at a discount of -511.51% from its 52-week high price of $8.50 and is indicating a discount of 0.0% from its 52-week low price of $1.39. Taking a look at company’s average trading volume of 6.85 million if we extend that period to 3-months.

For Pasithea Therapeutics Corp. (KTTA), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 2.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.05 in the current quarter.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Pasithea Therapeutics Corp. (NASDAQ:KTTA) trade information

Upright in the red during last session for losing -7.33%, in the last five days KTTA remained trading in the red while hitting it’s week-highest on Friday, 01/07/22 when the stock touched $1.39 price level, adding 10.9% to its value on the day. Pasithea Therapeutics Corp.’s shares saw a change of -21.47% in year-to-date performance and have moved -10.90% in past 5-day. Pasithea Therapeutics Corp. (NASDAQ:KTTA) showed a performance of -32.52% in past 30-days.

Wall Street analysts have assigned a consensus price target of $4.73 to the stock, which implies a rise of 70.61% to its current value. Analysts have been projecting $4.73 as a low price target for the stock while placing it at a high target of $4.73. It follows that stock’s current price would drop -240.29% in reaching the projected high whereas dropping to the targeted low would mean a loss of -240.29% for stock’s current value.

Pasithea Therapeutics Corp. (KTTA) estimates and forecasts

1 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $100k for the same. And 1 analysts are in estimates of company making revenue of $500k in the next quarter that will end on Mar 2022.

KTTA Dividends

Pasithea Therapeutics Corp. is more likely to be releasing its next quarterly report in February and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Pasithea Therapeutics Corp. (NASDAQ:KTTA)’s Major holders

Insiders are in possession of 35.83% of company’s total shares while institution are holding 9.28 percent of that, with stock having share float percentage of 14.46%. Investors also watch the number of corporate investors in a company very closely, which is 9.28% institutions for Pasithea Therapeutics Corp. that are currently holding shares of the company. Kepos Capital Lp is the top institutional holder at KTTA for having 0.4 million shares of worth $1.22 million. And as of Sep 29, 2021, it was holding 3.03% of the company’s outstanding shares.

The second largest institutional holder is Two Sigma Securities, LLC, which was holding about 10440.0 shares on Sep 29, 2021. The number of shares represents firm’s hold over 0.08% of outstanding shares, having a total worth of $31737.0.

>> 7 Top Picks for the Post-Pandemic Economy <<

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts



Download Free eBook For



100% free. stop anytime no spam